Challenges and Next Steps
While the results are promising, researchers warn that mouse models don’t fully emulate human cases of Alzheimer’s. Upcoming clinical trials must confirm diAcCA’s safety and efficacy in humans, a process that could take several years. Additionally, optimizing dosing regimens and long-term effects remain hurdles that researchers are working on. Global urgency surrounds this research, as Alzheimer’s cases in Europe alone are projected to double to 14 million by 2030. The rosemary compound for Alzheimer’s represents a beacon of hope for millions awaiting therapies that address the disease’s root causes rather than just its symptoms.